ADVERSE EVENTS OF NIMOTUZUMAB COMBINATION THERAPY IN PATIENTS WITH ADVANCED CARCINOMA

被引：0
|
作者：
Chen, L. [1 ]
Chen, H. [2 ]
Zhang, X. [3 ]
Ling, B. [5 ]
Dai, Y. [4 ]
Ma, G. [6 ]
Zheng, J. [6 ,7 ]
机构：
[1] Nanjing PLA Gen Hosp, Fuzhou, Peoples R China
[2] Jiangsu Canc Hosp, Nanjing, Peoples R China
[3] Chinese Peoples Liberat Army Gen Hosp, Beijing, Peoples R China
[4] China Med Univ, Grad Sch, Shenyang, Peoples R China
[5] HeBei Med Uinvers, Shijiazhuang, Hebei, Peoples R China
[6] Biotech Pharmaceut Co Ltd, Beijing, Peoples R China
[7] Tongji Univ, Sch Med, Shanghai 200092, Peoples R China
来源：
EJC SUPPLEMENTS | 2011年 / 9卷 / 01期
关键词：
D O I：
10.1016/j.ejcsup.2011.02.047
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：18 / 19
页数：2
相关论文
共 50 条
  • [1] Evaluation of the adverse event of nimotuzumab combined therapy in patients with advanced carcinoma
    Chen, L.
    Chen, H.
    Zhang, X.
    Liang, B.
    Zhang, G.
    Ma, G.
    Zheng, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [2] Incidence and impact of immune combination therapies adverse events in advanced renal cell carcinoma patients
    Catalano, Martina
    Venturi, Giulia
    Salfi, Alessia
    Bloise, Francesco
    Paolieri, Federico
    Galli, Luca
    Sisani, Michele
    Doni, Laura
    Roviello, Giandomenico
    IMMUNOTHERAPY, 2025,
  • [3] SIGNIFICANCE AND MANAGEMENT OF ADVERSE EVENTS ASSOCIATED WITH SYSTEMIC THERAPY WITH SORAFENIB IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA
    Hilgard, Philip
    Ertle, Judith M.
    Penndorf, Volker
    Haag, Sebastian
    Gerken, Guido
    HEPATOLOGY, 2008, 48 (04) : 962A - 962A
  • [4] Experience with combination of nimotuzumab and intensity-modulated radiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma
    Zhai, Rui-ping
    Ying, Hong-mei
    Kong, Fang-fang
    Du, Cheng-run
    Huang, Shuang
    Zhou, Jun-jun
    Hu, Chao-su
    ONCOTARGETS AND THERAPY, 2015, 8 : 3383 - 3390
  • [5] Nimotuzumab in the Combination With Neoadjuvant Chemotherapy Followed By Concurrent Chemoradiation Therapy for Locoregionally Advanced Nasopharyngeal Carcinoma Patients in Endemic Area: A Retrospective Study
    Fangzheng, W.
    Jiang, C.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2017, 99 (02): : E337 - E337
  • [6] Treatment-related adverse events and tolerability in patients with advanced renal cell carcinoma treated with first-line combination therapy with checkpoint inhibitors
    Htut, T. Win
    Swarup, S.
    Sultan, A.
    Mogollon-Duffo, F.
    Meda, S.
    Arevalo, M.
    Adhikari, N.
    Naing, P. T.
    Hlaing, P. P.
    Myat, Y. Mon
    Hardwicke, F.
    D'Cunha, N.
    Tijani, L.
    Thein, K. Z.
    ANNALS OF ONCOLOGY, 2019, 30 : 527 - 527
  • [7] Survival Impact of Glucocorticoid Administration for Adverse Events During Immune Checkpoint Inhibitor Combination Therapy in Patients with Previously Untreated Advanced Renal Cell Carcinoma
    Yoshino, Maki
    Ishihara, Hiroki
    Nemoto, Yuki
    Mizoguchi, Shinsuke
    Ikeda, Takashi
    Nakayama, Takayuki
    Fukuda, Hironori
    Yoshida, Kazuhiko
    Iizuka, Junpei
    Shimmura, Hiroaki
    Hashimoto, Yasunobu
    Kondo, Tsunenori
    Takagi, Toshio
    TARGETED ONCOLOGY, 2024, 19 (04) : 623 - 633
  • [8] Clinical effectiveness of 125I-Seed implantation in combination with nimotuzumab therapy for the advanced oral carcinoma: preliminary results
    Meng, J.
    Wang, X.
    Zhuang, Q. -W.
    Gu, Q. -P.
    Zhang, J.
    Li, Z. -P.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2014, 18 (21) : 3304 - 3310
  • [9] Tolerability and adverse events of sunitinib in Japanese patients with advanced renal cell carcinoma
    Nozawa, M.
    Oki, T.
    Okuda, Y.
    Minami, T.
    Hayashi, T.
    Nagae, S.
    Nishigaki, K.
    Mochida, Y.
    Uemura, H.
    EJC SUPPLEMENTS, 2009, 7 (02): : 430 - 431
  • [10] Management of Adverse Events Associated with Cabozantinib Treatment in Patients with Advanced Hepatocellular Carcinoma
    Schwartz, Gabriel
    Darling, Julianne O.
    Mindo, Malori
    Damicis, Lucia
    TARGETED ONCOLOGY, 2020, 15 (04) : 549 - 565
12345